Tokyo-based Eisai Co., Ltd. (Eisai) announced in March 2024 that its U.S. subsidiary Eisai Inc. will invest up to $15 million in medical laboratory C2N Diagnostics LLC (C2N) to support its goal to increase the availability, accessibility, affordability and use of blood-based tests for Alzheimer’s disease in the United States.
The new investment is in addition to the collaboration between C2N and Eisai announced in 2022 on the use of blood-based assays in clinical practice for diagnosing people living with dementia.
Through its highly precise research tool for identifying, monitoring and diagnosing Alzheimer’s, C2N has bolstered its global reputation as a pioneer in the early detection of the disease. With the new investment, Eisai highlighted its strong commitment to the development of novel and innovative drugs on a global scale.
Founded by Toyoji Naito more than 80 years ago, Eisai continues to live up to its objective to contribute to the health and well-being of people around the world, a mission shared by C2N Diagnostics.
“The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease,” said Keisuke Naito, Eisai’s global Alzheimer’s disease officer.
With Eisai’s much-welcomed infusion, C2N hopes to speed up the development and commercialization of its life-enhancing technology.
